IDH1 and cholangiocarcinoma: This came after a Phase 3 multicenter double-blind controlled trial for chemotherapy-refractory IDH1-mutated CCA with 185 patients found significantly increased progression-free survival (PFS) (HR 0.37; 95% CI: 0.25, 0.54; p < 0.0001) and longer (but not significantly increased) overall survival [43].